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Background: Autosomal dominant polycystic kidney disease (ADPKD) is responsible for 10% of cases of the end
stage renal disease. Early diagnosis, especially of potential fast progressors would be of benefit for efficient planning
of therapy. Urine excreted proteome has become a promising field of the search for marker patterns of renal
diseases including ADPKD. Up to now however, only the low molecular weight fraction of ADPKD proteomic
fingerprint was studied. The aim of our study was to characterize the higher molecular weight fraction of urinary
proteome of ADPKD population in comparison to healthy controls as a part of a general effort aiming at exhaustive
characterization of human urine proteome in health and disease, preceding establishment of clinically useful
disease marker panel.
Results: We have analyzed the protein composition of urine retentate (>10 kDa cutoff) from 30 ADPKD patients
and an appropriate healthy control group by means of a gel-free relative quantitation of a set of more than 1400
proteins. We have identified an ADPKD-characteristic footprint of 155 proteins significantly up- or downrepresented
in the urine of ADPKD patients. We have found changes in proteins of complement system, apolipoproteins,
serpins, several growth factors in addition to known collagens and extracellular matrix components. For a subset of
these proteins we have confirmed the results using an alternative analytical technique.
Conclusions: Obtained results provide basis for further characterization of pathomechanism underlying the
observed differences and establishing the proteomic prognostic marker panel.
Keywords: ADPKD, Urine proteome, Differential proteomics, Mass spectrometry, iTRAQ, MRMBackground
Autosomal dominant polycystic kidney disease (ADPKD)
is an inherited disorder affecting 1 in 1000 people and
responsible for 10% of cases of the end stage renal dis-
ease (ESRD). Apart from renal manifestations, changes
in other organs may be present, including a.o. liver cysts
and intracranial aneurysms. The disease is divided into
2 types based on mutated gene (PKD1 in type 1 - 85% of
cases, and PKD2 in type 2). The type of the mutation has
prognostic significance, as the average age of ESRD* Correspondence: michald@ibb.waw.pl
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reproduction in any medium, provided the ordepends on the type of the disease and amounts to
53 years in type 1, and 69 years in type 2 [1].
As potential therapeutic methods for ADPKD are
extensively tested in clinical trials [2-5], there is need
for tools which enable early diagnosis and monitoring
of therapy, especially non-invasive tests which would
substitute kidney biopsy. Evaluation of changes in the
peptidome and/or proteome may provide required in-
formation of pathophysiologic and clinical significance
and may allow to establish future diagnostic or prog-
nostic tools [6]. Urine, as well-accessible compartment,
seems to be an ideal material for the search of a non-
invasive prognostic and therapy monitoring tests in case
of renal diseases. However, before urine proteome or
peptidome markers become clinically useful, the urine
proteome itself must be thoroughly characterized in atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The study design. Combining 12 pooled samples into 3
IEF strips analysed in three LC-MS/MS experiments.
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ent sample processing and analysis experimental labora-
tory settings. The aim of our research was to apply an
in-depth proteomic bottom-up methodology to char-
acterize the urinary proteome of ADPKD population in
comparison to healthy controls.
Literature data concerning descriptive proteomics in
ADPKD patients are limited. Mason et al. reported the
proteomic analysis of four samples of cyst fluid obtained
postoperatively from excised kidneys in patients with
ESRD due to ADPKD [7]. Kistler et al. [8] were the first
who attempted to identify the urinary biomarker profile
of ADPKD, focusing on the low molecular (<15 kDa)
proteome fraction. It was thus of interest to explore other
sections of the proteome in search of the differences be-
tween ADPKD and control samples. In the present study
we have analyzed the proteome of the retentate of the
urine filtration on 10 kDa filters. Urine samples were col-
lected from 30 patients and carefully matched 30 healthy
controls selected without introducing any bias as to the
age and sex of the subjects in the aim to obtain possibly
general conclusions at the present stage of the research.
To obtain best possible coverage of the urine proteome
for relative quantitation the MS analysis was preceded by
a two dimensional tryptic peptides separation, the first
dimension being isoelectrofocusing (IEF) and the second
dimension – reversed phase liquid chromatography (LC).
In result a list of more than 1400 proteins was estab-
lished, represented by more than two peptides and
subjected to comparative analysis yielding a set of 155
proteins the levels of which were different in ADPKD
and control samples.
Results
The proteome of urine collected from 30 ADPKD
patients and 30 healthy subjects was compared using a
combined IEF-LC-MS-MS/MS relative quantitation of
iTRAQ labeled tryptic peptides. From each sample an
equal amount of total protein obtained in urine retentate,
after filtration on >10 kDa cutoff filters, was used for the
analysis. This allowed to normalise the sample set with
respect to different levels of dilution of proteome in each
sample and to compare the proteome composition. After
tryptic digestion peptides were subjected to iTRAQ
labeling and IEF separation yielding 26 fractions, each
analysed in a separate LC-MS-MS/MS run. IEF separ-
ation substantially increases the final protein coverage.
However, the separate analysis of 60 samples including
IEF step would require more than 1500 LC-MS-MS/MS
runs which is not practical. To overcome this difficulty
and retain an in depth insight into urine proteome we
have used a partial pooling strategy. A set of 30 ADPKD
samples was divided into 3 subsets, containing 10 sam-
ples each, which were pooled into three Disease PooledSamples (DPS I, II and III). Similarly, control set was
divided into three Control Pooled Samples (CPS I, II and
III) retaining age and sex matching within the subsets. In
addition two technical replicates of each DPS or CPS was
prepared, further denoted A or B to assess the intragroup
technical variability.
In result 4-plex iTRAQ labeled peptides from three
replicates of pooled control and ADPKD samples, each
of them represented by two technical replicates, were
analyzed during IEF-LC-MS-MS/MS analysis of three
IEF strips, as described in Methods section and Figure 1.
For each of IEF strips the two pairs of control pooled
samples, for instance CPS IA, and CPS IIA, and two dis-
ease pooled samples, for instance DPS IA and DPS IIA
were mixed and subjected to IEF separation. IEF strips
were cut into ca. 26 sections. Labeled peptides were
eluted from each of the IEF strip sections and subjected
to separate LC-MS-MS/MS runs. In result of qualitative
analysis (peptide and protein identification) in each of
the three IEF-LC-MS-MS/MS experiments 1327/1353/
1582 proteins, respectively, were identified, each repre-
sented by more than two peptides, as shown in Table 1
and Figure 2. One-peptide hits were not taken into ac-
count in further quantitative analysis.
Qualitative results (protein lists) from three IEF-LC-
MS-MS/MS experiments were combined, resulting in a
dataset with all 1700 proteins identified by at least two
peptides. Within this dataset protein identifications
based on identical peptide sets were again grouped and
each group was treated as a single protein cluster in fur-
ther processing. Quantitative analysis was performed, as
described in Methods section, with proteins represented
by two or more peptides for which it was possible to cal-
culate a protein ratio in at least one of IEF-LC-MS-MS/
MS experiments. The final combined protein list accepted
for quantitation contained 1413 proteins. 1090 out of
Table 1 Number of identified peptides and proteins in






(proteins ≥ 2 peptides)
1 9530 2430 (1327)
2 9814 2637 (1353)
3 11329 2810 (1582)
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experiment.
The statistical analysis of the quantitative results of the
three IEF-LC-MS-MS/MS experiments revealed 155
proteins that were differently populated (with q < 0.05)
in the urine of ADPKD patients as compared to healthy
controls. 148 of them were identified in each of the
IEF-LC-MS-MS/MS experiment, 7 – in two replicates.
The Differential Protein List (DPL) is presented in
Table 2. The differences in protein levels (protein ratio)
can be substantial, exceeding 5-fold in some cases.
Among DP’s, 103 proteins were downregulated, and
52 were upregulated in ADPKD. Principal Component
Analysis of the results of this experiment (Figure 3)
shows a very good separation of the two study groups
along the first component axis.
DPL was obtained as a result of pooling experiment
and this approach allowed for in-depth (>1000 proteins)
quantitative analysis of urine proteome. However, uponFigure 2 Results of qualitative analysis – a Venn diagram
representing the number of proteins identified by two or more
peptides in three biological replicates of iTRAQ experiment –
three IEF gel strips. 1090 proteins are common in all three
experiments.pooling the levels of proteins are averaged and the infor-
mation on the variability of the amount of the protein
among individual samples is lost. Therefore, to test the
pooling experiment results using an alternative analytical
approach (Multiple Reaction Monitoring - MRM), we
have carried out the analysis of individual ADPKD and
control samples for a subset of proteins from DPL.
For this purpose a new set of samples (27 ADPKD vs.
25 healthy controls) was collected. Initially, a subset of
17 proteins from DPL, represented by the largest number
of peptides was selected for MRM analysis. The number
of proteins for MRM experiment is limited by the num-
ber of peptides that can be analysed in parallel in a single
experiment. For these proteins their natural abundance
peptides were searched for in urine control samples.
Satisfactory results were obtained for 9 (represented by
14 peptides) out of 17 proteins, due to insufficient sensi-
tivity for 8 remaining proteins. Next, 14 stable isotopic-
ally labeled (SIS internal standards) peptides were
synthesized. Using SIS peptides the MS parameters for
MRM experiment were optimised for each peptide.
Comparison of the results of the MRM quantitation
with the results of iTRAQ pooling experiment for
these 9 proteins is shown in Table 3. For 8 proteins their
upregulation in ADPKD was in agreement with the
results of the pooling experiment, however for one pro-
tein (Cystatin-M) the q-value (0.13) exceeded the thresh-
old of 0.05 making this result insignificant. For still
another protein (Proactivator polypeptide) MRM results
for the representing peptide EIVDSYLPVILDIIK indicate
its smaller level in ADPKD whereas in pooling experi-
ment the level averaged over 19 peptides was larger in
ADPKD. This result is difficult to explain since the
same peptide EIVDSYLPVILDIIK in iTRAQ pooling ex-
periment shows increased level in ADPKD, so for this
protein MRM does not confirm results from pooling
analysis. However, for 8 out of 9 proteins the results
of both approaches are in full qualitative agreement.
On the quantitative level the agreement between the two
methods in the case of majority of proteins is good, only
for 2 proteins the ratio differences are larger (for Retinol
binding protein (RBP) ratio 4.6 for MRM and 2.65 for
iTRAQ). It has to be taken into account that the ratios
are calculated in both methods using a different set of
peptides, usually much larger for iTRAQ. These peptides
may represent different regions of protein sequence and
some of them may originate from proteolytic protein
fragments, quite probable in urine proteome and not
from intact proteins, which may justify the observed dif-
ferences on quantitative level. An alternative explanation
in case of RBP comes from higher variability level of this
protein within ADPKD group, as illustrated in Figure 4.
It shows that the upregulation of an average RBP level in
ADPKD originates from a subset (6 samples out of 27) of
Table 2 Differential Protein List. Proteins of different level in the urine of ADPKD patients compared to healthy
controls. Ratio is given as ADPKD/Control
no protein qvalue ratio peptides description
1 P01019 0.00003 1.7 33 Angiotensinogen
2 P01008 0.00003 2.01 28 Antithrombin-III
3 P01023 0.00003 3.16 62 Alpha-2-macroglobulin
4 Q9NZP8 0.00003 0.59 23 Complement C1r subcomponent-like protein
5 Q93088 0.00003 0.55 23 Betaine–homocysteine S-methyltransferase 1
6 Q16769 0.00003 0.51 24 Glutaminyl-peptide cyclotransferase
7 P02753 0.00003 2.65 11 Retinol-binding protein 4
8 P19013 0.00003 0.3 16 Keratin, type II cytoskeletal 4
9 P19835 0.00003 0.54 27 Bile salt-activated lipase
10 P00746 0.00003 5.44 14 Complement factor D
11 P12109 0.00003 0.53 43 Collagen alpha-1(VI) chain
12 P33908 0.00003 0.48 25 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA
13 Q8WZ75 0.00003 0.41 16 Roundabout homolog 4
14 P02774 0.00003 1.78 24 Vitamin D-binding protein
15 P43652 0.00003 1.7 20 Afamin
16 Q8N307 0.00003 0.44 9 Mucin-20
17 Q9HCU0 0.00003 0.52 15 Endosialin
18 P02787 0.00003 1.84 70 Serotransferrin
19 P07602 0.00003 2.74 23 Proactivator polypeptide
20 P02679 0.00003 2.89 9 Fibrinogen gamma chain
21 P02763 0.00003 1.94 45 Alpha-1-acid glycoprotein 1
22 P00915 0.00003 3.21 12 Carbonic anhydrase 1
23 P02675 0.00003 2.17 14 Fibrinogen beta chain
24 Q13867 0.00003 0.38 10 Bleomycin hydrolase
25 P19823 0.00003 1.77 26 Inter-alpha-trypsin inhibitor heavy chain H2
26 P02647 0.00003 3.89 26 Apolipoprotein A-I
27 Q5SZK8 0.00003 0.6 22 FRAS1-related extracellular matrix protein 2
28 Q16270 0.00003 0.45 13 Insulin-like growth factor-binding protein 7
29 P36955 0.00003 2.51 25 Pigment epithelium-derived factor
30 P06727 0.00003 4.19 39 Apolipoprotein A-IV
31 P01024 0.00003 2.45 94 Complement C3
32 P61769 0.00003 3.69 21 Beta-2-microglobulin
33 Q6EMK4 0.00003 0.46 26 Vasorin
34 P20930 0.00003 0.51 33 Filaggrin
35 P02768 0.00003 1.69 191 Serum albumin
36 P01009 0.00003 1.64 99 Alpha-1-antitrypsin
37 P04114 0.00003 3.34 14 Apolipoprotein B-100
38 P31944 0.00003 0.44 15 Caspase-14
39 P04264 0.00003 1.81 44 Keratin, type II cytoskeletal 1
40 P24592 0.00003 5.08 3 Insulin-like growth factor-binding protein 6
41 O00533 0.00003 0.51 17 Neural cell adhesion molecule L1-like protein
42 P01133 0.00003 0.59 78 Pro-epidermal growth factor
43 P04180 0.00003 0.56 16 Phosphatidylcholine-sterol acyltransferase
44 P0C0L5 0.00003 1.4 83 Complement C4-B
45 P02652 0.00003 1.92 12 Apolipoprotein A-II
46 P05154 0.00003 0.38 38 Plasma serine protease inhibitor
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Table 2 Differential Protein List. Proteins of different level in the urine of ADPKD patients compared to healthy
controls. Ratio is given as ADPKD/Control (Continued)
47 P00738 0.00003 2.21 26 Haptoglobin
48 P08582 0.00003 0.54 20 Melanotransferrin
49 P05546 0.00003 2.32 13 Heparin cofactor 2
50 Q9UBC9 0.00006 0.49 18 Small proline-rich protein 3
51 P15151 0.00008 0.55 19 Poliovirus receptor
52 P04196 0.00008 1.81 14 Histidine-rich glycoprotein
53 P02766 0.00008 1.88 11 Transthyretin
54 P05090 0.00013 0.46 12 Apolipoprotein D
55 Q8NBJ4 0.00023 0.52 14 Golgi membrane protein 1
56 P04746 0.00025 0.7 84 Pancreatic alpha-amylase
57 P39059 0.00029 0.64 17 Collagen alpha-1(XV) chain
58 Q9UN70 0.00038 0.6 17 Protocadherin gamma-C3
59 P08473 0.00049 0.59 27 Neprilysin
60 Q00887 0.00069 5.04 4 Pregnancy-specific beta-1-glycoprotein 9
61 P78380 0.00082 0.56 10 Oxidized low-density lipoprotein receptor 1
62 Q99574 0.00082 0.59 20 Neuroserpin
63 P02790 0.00083 1.56 41 Hemopexin
64 Q99972 0.00134 2.39 8 Myocilin
65 P19827 0.00134 1.39 13 Inter-alpha-trypsin inhibitor heavy chain H1
66 Q6V0I7 0.00142 0.51 14 Protocadherin Fat 4
67 P02144 0.00175 3.59 5 Myoglobin
68 P55287 0.0019 0.63 21 Cadherin-11
69 Q9UQ72 0.00203 5.92 3 Pregnancy-specific beta-1-glycoprotein 11
70 P55290 0.00212 0.67 25 Cadherin-13
71 Q8IYS5 0.00221 0.55 12 Osteoclast-associated immunoglobulin-like receptor
72 Q9H8L6 0.00255 0.58 12 Multimerin-2
73 Q9NY97 0.00271 0.44 6 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2
74 O43505 0.0032 0.52 9 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase
75 P08571 0.00376 0.64 23 Monocyte differentiation antigen CD14
76 Q15828 0.00399 1.85 10 Cystatin-M
77 Q8TF66 0.00411 0.46 6 Leucine-rich repeat-containing protein 15
78 P02538 0.00417 0.57 38 Keratin, type II cytoskeletal 6A
79 P40197 0.00467 0.46 6 Platelet glycoprotein V
80 P00751 0.00492 1.66 16 Complement factor B
81 Q9BRK3 0.0055 0.67 19 Matrix-remodeling-associated protein 8
82 Q14393 0.00553 0.56 10 Growth arrest-specific protein 6
83 Q13508 0.00569 2.49 11 Ecto-ADP-ribosyltransferase 3
84 Q8IUL8 0.00569 0.61 14 Cartilage intermediate layer protein 2
85 P22105 0.00569 0.75 58 Tenascin-X
86 P54710 0.00569 0.4 4 Sodium/potassium-transporting ATPase subunit gamma
87 P07737 0.00581 2.42 5 Profilin-1
88 Q12860 0.00584 0.69 27 Contactin-1
89 Q86UN3 0.00622 0.61 8 Reticulon-4 receptor-like 2
90 P50995 0.00632 0.59 11 Annexin A11
91 P11597 0.00632 0.51 7 Cholesteryl ester transfer protein
92 Q9BRK5 0.00684 0.58 8 45 kDa calcium-binding protein
93 P35555 0.00684 0.72 15 Fibrillin-1
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Table 2 Differential Protein List. Proteins of different level in the urine of ADPKD patients compared to healthy
controls. Ratio is given as ADPKD/Control (Continued)
94 P55285 0.007 0.59 11 Cadherin-6
95 O75223 0.0075 0.63 8 Gamma-glutamylcyclotransferase
96 O75368 0.00794 2.03 5 SH3 domain-binding glutamic acid-rich-like protein
97 P51654 0.008 0.57 12 Glypican-3
98 Q9UKU9 0.00801 0.61 10 Angiopoietin-related protein 2
99 O43155 0.00801 0.59 12 Leucine-rich repeat transmembrane protein FLRT2
100 P05451 0.00803 1.7 13 Lithostathine-1-alpha
101 P29622 0.00882 0.57 14 Kallistatin
102 P02751 0.01028 0.8 90 Fibronectin
103 P98160 0.01045 0.75 115 Basement membrane-specific heparan sulfate proteoglycan core protein
104 P01031 0.01113 1.9 8 Complement C5
105 P20774 0.01175 2.5 4 Mimecan
106 Q5IJ48 0.01317 0.51 7 Crumbs homolog 2
107 Q16661 0.01319 3.75 3 Guanylate cyclase activator 2B
108 P49221 0.01365 0.67 12 Protein-glutamine gamma-glutamyltransferase 4
109 P22792 0.01403 0.64 13 Carboxypeptidase N subunit 2
110 P16444 0.0143 0.66 25 Dipeptidase 1
111 P35052 0.01447 0.68 16 Glypican-1
112 O14498 0.0148 0.63 12 Immunoglobulin superfamily containing leucine-rich repeat protein
113 O94910 0.01483 0.6 8 Latrophilin-1
114 P02511 0.01487 0.49 6 Alpha-crystallin B chain
115 Q9NRX4 0.01598 0.68 10 14 kDa phosphohistidine phosphatase
116 Q9BY67 0.01829 0.68 26 Cell adhesion molecule 1
117 P19022 0.01885 0.65 21 Cadherin-2
118 P27169 0.01891 3.48 2 Serum paraoxonase/arylesterase 1
119 Q7Z5N4 0.01891 0.61 7 Protein sidekick-1
120 O00391 0.01951 0.72 33 Sulfhydryl oxidase 1
121 Q8TB96 0.01951 0.56 6 T-cell immunomodulatory protein
122 P08603 0.01953 1.65 11 Complement factor H
123 O75340 0.02011 0.56 6 Programmed cell death protein 6
124 Q8IZF2 0.02011 0.57 9 Probable G-protein coupled receptor 116
125 Q08174 0.02013 0.65 30 Protocadherin-1
126 Q9UGT4 0.02173 0.66 23 Sushi domain-containing protein 2
127 Q15223 0.02277 0.6 7 Poliovirus receptor-related protein 1
128 P09467 0.02277 0.75 17 Fructose-1,6-bisphosphatase 1
129 P10253 0.02277 0.75 108 Lysosomal alpha-glucosidase
130 P04745 0.02277 0.47 5 Alpha-amylase 1
131 P15144 0.0253 0.71 73 Aminopeptidase N
132 Q8N271 0.02628 0.65 14 Prominin-2
133 Q9HBB8 0.02658 0.6 11 Mucin and cadherin-like protein
134 P21266 0.02672 0.65 5 Glutathione S-transferase Mu 3
135 P30530 0.0298 0.62 16 Tyrosine-protein kinase receptor UFO
136 Q08554 0.03104 3.06 2 Desmocollin-1
137 P20472 0.03378 0.52 5 Parvalbumin alpha
138 P13598 0.03484 0.63 7 Intercellular adhesion molecule 2
139 P10643 0.03556 2.02 5 Complement component C7
140 P43121 0.03723 0.65 14 Cell surface glycoprotein MUC18
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Table 2 Differential Protein List. Proteins of different level in the urine of ADPKD patients compared to healthy
controls. Ratio is given as ADPKD/Control (Continued)
141 Q08380 0.03793 0.73 41 Galectin-3-binding protein
142 O75487 0.0383 0.72 9 Glypican-4
143 O75339 0.04059 0.49 5 Cartilage intermediate layer protein 1
144 P02649 0.04059 0.69 18 Apolipoprotein E
145 P34059 0.04062 0.73 17 N-acetylgalactosamine-6-sulfatase
146 P35318 0.04219 0.49 4 ADM
147 Q12794 0.04254 0.58 7 Hyaluronidase-1
148 A9Z1Y9 0.04254 2.01 3 Thymosin beta-4-like protein 6
149 O14773 0.04437 0.69 22 Tripeptidyl-peptidase 1
150 O75015 0.04588 0.6 9 Low affinity immunoglobulin gamma Fc region receptor III-B
151 P30711 0.04618 0.4 2 Glutathione S-transferase theta-1
152 Q14894 0.04647 0.62 6 Mu-crystallin homolog
153 O43895 0.04733 0.68 18 Xaa-Pro aminopeptidase 2
154 Q9NQS3 0.04733 0.59 10 Poliovirus receptor-related protein 3
155 P04792 0.04848 0.59 7 Heat shock protein beta-1
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much larger (even by a factor of 25) than in remaining
ADPKD samples, for which the levels are similar to con-
trol. Thus the average value in pooling experiment might
easily be shifted by a single sample of exceptionally large
content of RBP. Interestingly, the RBP levels correlate
strongly with the progressor status of the patient, as illu-
strated by asterisks in Figure 4. This effect however
requires further studies.Figure 3 Principal Component Analysis of the three pooled biologica
and III) samples based on 155 proteins (grey dots) indicated in the an
samples. The analysis shows a good separation of control samples from A
control samples. Normalized heights of iTRAQ peptide signals (averaged ov
analysis. Values of each biological replicate is an average over the two techDiscussion
Urine proteome is thought to contain renal disease
fingerprints, but the pathology-related urine proteomics
is still in its infancy. For ADPKD one study [8] was pub-
lished in which a low molecular weight proteome frac-
tion was studied and a set of potential disease markers
was proposed. However, the most successful approach of
global proteomic analyses of the total proteome, combin-
ing multiple steps of separation preceding quantitativel replicates of control (CPS I, II, and III) and disease (DPS I, II
alysis as differentially populated between control and ADPKD
DPKD samples along the first component axis. Note a high similarity of
er the corresponding protein cluster) were used as features in the PCA
nical replicates.
Table 3 Comparison of the results of the MRM quantitation with the results of iTRAQ pooling experiment for
9 proteins. Protein ratios along with q-values are given
PROTEIN MRM iTRAQ
ratio p-value ratio q-value peptides
1. Antithrombin-III 3.56 0.0001 2.01 0.00003 28
2. Apolipoprotein A-IV 3.65 0.001 4.19 0.00003 39
3. Complement C3 2.54 0.001 2.45 0.00003 94
4. Histidine-rich glycoprotein 1.79 0.002 1.81 0.00008 14
5. Proactivator polypeptide 0.55 0.002 2.74 0.00003 23
6. Myocilin 1.99 0.007 2.39 0.00134 8
7. Retinol-binding protein 4 4.6 0.015 2.65 0.00003 11
8. Transthyretin 2.87 0.025 1.88 0.00008 11
9. Cystatin-M 1.64 0.129 1.85 0.00399 10
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urine samples. To fill this gap, in our approach we
have combined iTRAQ based quantitation with peptide
isoelectrofocusing and reversed phase separation coupled
with MS to obtain an in-depth urine proteome coverage
of quantitative analysis of ADPKD vs. control sample set.
Qualitative analysis – combined from three IEF-LC-
MS-MS/MS experiments peptide identification brought
a list of 14429 peptides assigned to proteins, correspond-
ing to 1700 proteins, each identified by at least two pep-
tides (Additional file 1). The median number of peptides
per protein was 9.34. This list compares well with other
attempts of qualitative characterization of human urine
proteome in which the overall number of proteins
depends strongly on the number of peptide/protein pre-
fractionation steps used. 808 proteins were detected whenFigure 4 Retinol-binding protein (RBP) levels as measured by MRM te
Note large differences in protein levels within ADPKD group and correlatio
by asterisks).the only separation step was LC preceding MS [9]. Adding
1D SDS PAGE separation step increased this number to
1102 [10] or 1543 [11] proteins represented by at least
two peptides. Application of multidimensional separation
strategy was shown to yield 2362 proteins [12], but the
other group reports only 991 proteins [13]. Pairwise
comparison of common proteins detected in our work
yields 972 common proteins with Adachi [11], and 975
with 1823 proteins (including one-peptide hits) found by
Li [13]. The number of common proteins detected in
three publications [10,11,13] was compared in Figure 2
in Marimuthu's paper [10] yielding 658 common proteins
of which 582 were detected in our work. This number
correlates well with 587 proteins named “core urinary
proteins” commonly detected in a large set of urine
samples [9]. In conclusion our dataset represents verychnique in a set of 27 ADPKD/25 healthy control samples.
n of its high levels with progressor status of the patient (denoted
Bakun et al. Clinical Proteomics 2012, 9:13 Page 9 of 13
http://www.clinicalproteomicsjournal.com/content/9/1/13well core urinary proteins, however the number of
unique proteins found in this work is also high, indi-
cating that the urine proteome complexity is far from
being explored in-depth.
In a quantitative analysis a list of proteins (DPL)
differentiating ADPKD vs. healthy control samples has
been established. The partial pooling experiment indi-
cated a list of 155 proteins of different level in the
urine of ADPKD patients compared to healthy sub-
jects. We have found alterations in the complement
system, apolipoproteins, group of serine protease inhi-
bitors, several growth factors, collagen chains, extracel-
lular matrix components, transmembrane proteins, and
many others. Many of them have never been linked to
ADPKD in previous studies. Additionally, our results
confirm the alterations observed in animal models, con-
cerning, for example, apolipoproteins [14]. Some proteins
included in DPL have previously been linked to the
progression of cystic kidney disease, for example CD14
molecule [15].
In our study the application of a pre-separation of
peptides by IEF and the analysis of 26 fractions of each
gel allowed to greatly increase the number of proteins
that could be subjected to quantitation. However, each
IEF-LC-MS-MS/MS experiment required 26 LC-MS-MS/
MS runs corresponding to 78 hours of spectrometer
time, so it could not be carried out separately for 60
samples due to exceedingly long time of the analysis
required (4500 hours, nearly 200 days of spectrometer
time would be required). This justified the pooling ap-
proach which combined the information contained in
all samples and allowed its in-depth analysis in a rea-
sonable time. However, when the protein ratios are
compared after pooling the information on the scatter
of protein ratios among the individual, pooled samples
is lost, and the statistical validity of obtained differ-
ences cannot be properly assessed. For that reason we
have used MRM technique for a subset of nine DPL pro-
teins, which confirmed the results of the pooling experi-
ment, only for one protein the confirmatory analysis was
not successful. In general the differential list obtained
from pooling experiment is thus a candidate list, each
protein of interest from the list has to be measured in
individual samples in a separate experiment by an in-
dependent method.
Only a few cases of proteomic analysis of ADPKD tis-
sue samples can be found in the literature. Mason et al.
reported the proteomic analysis of four samples of cyst
fluid obtained postoperatively from excised kidneys in
patients with ESRD due to ADPKD [7]. The authors
identified 44 proteins that were found in at least two
cysts and might be of mechanistic or diagnostic interest
in ADPKD. Similarly to our results, the list of these pro-
teins included complement factors, apolipoprotein A-I,pigment epithelium-derived factor (PEDF) and others.
However, the potential diagnostic utility of cyst fluid pro-
teomics is highly limited, and in our opinion, it is the
urine that may become the diagnostic material in clinical
practice.
Kistler et al. were the first who attempted to identify
the urinary biomarker profile of ADPKD [8]. Due to ap-
plication of CE-MS technology the range of molecular
masses under study was thus limited to less than 15 kDa,
whereas in our work proteins of masses larger than
10 kDa were studied. This explains the differences in the
lists of differentiating proteins which in case of Kistler
et al. were limited mainly to collagen fragments and uro-
modulin peptides. Therefore, our DPL may be regarded
as a complete list of ADPKD-specific urinary proteins,
independent on kidney function.
Our results provide the first step of the analysis, spe-
cific DPL proteins of interest should be now verified by
a targeted analysis on non-pooled samples on much
wider sample sets. Moreover, the specificity of these
results should be determined in studies including
patients with chronic kidney disease of distinct origin.
Additionally, it should be determined whether the type
of mutation (PKD1 or PKD2) impacts the proteome.
Finally, methods of sample collection and preparation,
laboratory procedures, and data analysis must be opti-
mized. After verification, our results may in future
serve as a basis for mechanistic studies and, therefore,
may ultimately lead to discovery of new therapeutic
targets in ADPKD. Additionally, the set of urinary bio-
markers may be used in the future for early diagnosis
of ADPKD.
Conclusions
The urine proteome of ADPKD patients differs signifi-
cantly from the urine proteome of healthy subjects and
may become the clinical tool used for early diagnosis of
ADPKD. The pathophysiological informations obtained
in presented study may become a basis for the develop-
ment of new therapies.
Methods
Urine samples
Thirty ADPKD patients diagnosed with abdominal ultra-
sound [16] were enrolled into the study group. The con-
trol group consisted of 30 healthy volunteers matched
according to the sex and age. The demographic data of
both groups are summarized in Table 4. The inclusion
criteria for the study group were the diagnosis of ADPKD
and age ≥18 years. The inclusion criteria for the control
group included: absence of ADPKD, age ≥18 years, and
body mass index (BMI) between 21 and 26. The exclu-
sion criteria for both groups included especially: current
infection of urinary tract, macroscopic hematuria,
Table 4 Demographic characteristics and renal function
of study and control group
Study group Control group
n 30 30
male/female (%) 12 (40%)/18 (60%) 12 (40%)/18 (60%)
mean age in years (range) 44.4 (20–72) 44.6 (20–76)
mean body mass in kg (range) 70.7 (50–100) 71.1 (50–91)
mean serum creatinine in
μmol/l (range)
120.7 (38.1-388.9) 68.4 (45.8-114.4)
GFR (CKD-EPI formula) in
ml/min (range)
66.8 (11–140) 102.2 (54–136)
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ized malignancy of other system, and status post organ
transplantation.
The study protocol was approved by the local ethics
committee. Informed consent was obtained from all par-
ticipants. The study was performed in accordance with
the Declaration of Helsinki Principles.
Urine collection
Samples were collected from 30 patients and 30 healthy
donors using a uniform protocol. The second or third-
morning mid-stream urine was collected from all partici-
pants at a time of 1 and 3 hours after previous micturition.
Sterile urine containers were used for the collection of
samples. pH of the samples was stabilized at 7.2 by
addition of 1/10th vol. of 1 M HEPES pH 7.2 immediately
after collection. Further sample preparation steps were
carried out within 1 hour after collection during which
the sample was kept at room temperature. Samples were
vortexed for 2 minutes, centrifuged (3000xg, room temp.)
for 10 minutes to clear the debris, filtered through the
0.4 μm filter (Rotilabo-Spritzenfilter, P819.1, Roth) and
portioned into 1 ml aliquots, to avoid freeze/thaw cycles
in repeated experiments of the same sample. Sample
aliquots were stored at −80°C for further use. The
protocol used follows the urine proteomic sample col-
lection recommendations [17].
Sample filtration
10 kDa cutoff membrane filters (Amicon Ultra-0.5,
UFC501096, Millipore) were washed twice with MilliQ
water prior to use. Urine was centrifuged through the
membrane at 14000xg for 15 minutes. Next, 500 μl MQ
was added to the retentate and centrifugation step was
repeated. To recover the concentrated and desalted
sample, the filter was placed upside down in a clean
micro centrifuge tube and centrifuged for 2 minutes
at 1000xg. The protein concentration was measured
by the Bradford method. Aliquots of samples were
stored at −80°C.Pooling samples and iTRAQ-labelled samples study
design
When indicated, the aliquots (corresponding to 10 μg of
protein) of 10 urine samples were pooled. Only samples
from a single study group (disease or control) were
pooled. 30 control (healthy) samples were divided into
three control pooled samples (CPS’s I, II and III) and
similarly, 30 ADPKD samples were divided into three
disease pooled samples (DPS’s I, II and III). Age and sex
matching was preserved within the three pairs of pooled
sample groups. Three CPS’s and three DPS’s were
obtained in two technical replicates (marked A and B)
each, making a set of 12 pooled samples to be compared
after iTRAQ labeling. As 4-plex iTRAQ was used, 2 CPS
and 2 DPS samples were compared in one LC-MS/MS
experiment. To analyze 12 samples we have carried out
a set of 3 independent LC-MS/MS experiments. The
study design is illustrated in Figure 1.
iTRAQ labeling
Before labeling, protein aliquots were evaporated to dry-
ness in a speedvac, dissolved in 20 μl Dissolution Buffer
with 0.1% SDS, reduced with TCEP, cysteine-blocked
with MMTS (reagents were provided with the iTRAQ
kit from Applied Biosystems), and digested overnight
with trypsin (Promega). The CPS and DPS samples were
differentially labeled with one of the four iTRAQ tags
(114, 115 for CPS samples and 116, 117 for DPS samples)
for 1 h according to the iTRAQ manufacturer’s protocol.
Next, the reaction was quenched by adding 100 μl H2O.
For each of the three LC-MS/MS experiments 2 CPS
and 2 DPS iTRAQ-labeled samples were combined and
340 μl buffer was added [8 M urea, 0.2% IPG buffer pH
3–11 NL (GE Healthcare), 0.002% bromophenol blue in
50 mM Tris–HCl, pH 8.0]. The solution was applied to
18 cm IPG strip with 3–11 NL pH gradients (GE Health-
care) for isoelectrofocusing (IEF): 340 μl of sample/strip,
corresponding to 400 μg protein. The IPG strip was rehy-
drated overnight in an IPG box (GE Healthcare). The
next day, the strips were isoelectrofocused using a Ettan
IPGphor 3 electrophoresis system (GE Healthcare) as
follows. Two steps of electrophoresis were used. The
first step consisted of a 5 h pre-run at 500 V. During this
step, the conductivity decreases, and salts and other
highly conductive compounds move towards the elec-
trode (anode). Second, a long gradient focusing program
was used: 1 h at 500 V, 9 h at 1000 V and 30 h at
8000 V (the final current was 5 μA).
After focusing, the strip was removed from the tray
and the overlay oil was blotted with a paper tissue. Strip
was wrapped in a parafilm and stored at −80°C. The strip
was placed on a tray cooled with dry ice and cut into
sections of ca. 7 mm. The sections were transferred
into individual 1.5-ml siliconized Eppendorf tubes. In all,
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Peptides were extracted from gel sections by two cycles
of adding 60 μl 0.1%TFA, 2% acetonitrile and vortexing
the tubes for 40 minutes at room temperature. Aliquots
with extracted peptides were stored at −80°C for LC-MS/
MS analysis.
Mass spectrometry - LC-MS/MS settings
The peptide mixture (20 μl) was applied to the
nanoACQUITY UPLC Trapping Column (Waters) using
water containing 0.1% formic acid as the mobile phase
and then transferred to the nanoACQUITY UPLC BEH
C18 Column (Waters, 75 μm inner diameter; 250-mm
long) using an acetonitrile gradient (3–33% acetonitrile
over 150 minutes) in the presence of 0.1% formic acid
with a flow rate of 250 nl/min. The column outlet
was directly coupled to the electrospray ion source of
the LTQ-Orbitrap Velos mass spectrometer (Thermo
Scientific) working in the regime of data-dependent MS
to MS/MS switch. HCD fragmentation was used. Other
Orbitrap parameters were as follows: one MS scan was
followed by max. 5 MS/MS scans, capillary voltage was
1,5 kV, data were acquired in positive polarity mode.
Mass spectrometry - Qualitative MS/MS data processing
The acquired MS/MS data were pre-processed with
Mascot Distiller (version 2.3.2.0, Matrix Science, London,
UK). The database search of the data using MASCOT
search engine was carried out in a three-step procedure
(described elsewhere [18], and in short in Additional
file 2) to calculate MS and MS/MS measurements errors
and to recalibrate the data for the repeated MASCOT
search. The initial search parameters were set as follows:
enzyme, semi-trypsin; fixed modification, cysteine modi-
fication by MMTS as well as iTRAQ labeling of the
N-terminus of peptides and of lysine side chains; variable
modifications - oxidation (M); max missed cleavages – 1,
Swiss-Prot database with the taxonomy restricted to
Homo sapiens (20273 sequences). For the repeated
search the recalibrated data from all gel sections were
merged into one input file and searched using MASCOT
against a Swiss-Prot database supplemented with the
decoy database to obtain the statistical assessment of the
identification of each peptide by a joined target/decoy
database search strategy [19]. This procedure provided
q-value estimates for each peptide spectrum match
(PSM) in the dataset. All PSMs with q-values > 0.01 were
removed from further analysis. A protein was regarded
as confidently identified if at least two peptides of this
protein were found. Proteins identified by a subset of
peptides from another protein were excluded from ana-
lysis. Proteins that exactly matched the same set of
peptides were clustered into one group/cluster. MS/MS
spectra of peptides meeting the above acceptancecriteria were subjected to quantitative analysis step to
obtain a list (Differential Protein List) of proteins dif-
ferentially populated between a set of three CPS’s and
three DPS’s.
iTRAQ quantitative analysis
For protein quantitation only unique peptides (i.e. peptides
belonging only to one protein/cluster) were included. In
the first step, using MascotDistiller program iTRAQ re-
porter ion peaks were detected in the preprocessed
MS/MS spectra; next, their intensities were corrected
for isotope impurity using the information provided
by the reagent manufacturer. For each spectrum a
geometric mean of two reporter ion intensities belong-
ing to one study group (CPS or DPS) were separately
calculated. A ratio of these mean values (CPS mean
divided by DPS mean) was reported as peptide ratio.
If more than one spectrum was obtained for a peptide
in a single LC-MS/MS experiment, median peptide ratio
value from all spectra was used. Prior to the protein ratio
calculations, peptide ratios were median-normalized to re-
move systematic bias. Proteins ratios were calculated as
the median ratio of their peptide’s ratios. The statistical
significance of a single protein ratio was assessed by an in
house program Diffprot [20]. In this program the statis-
tical validity of regulation/expression status of the protein
represented by its calculated protein ratio is based solely
on the statistical analysis of the set of all MS/MS datasets
from a given experiment, without assumptions on the
character of the distribution of peptide ratios in a dataset
(e.g. its normality). In brief, the probability of obtaining a
given protein ratio by a random selection from the dataset
is tested by multiple rounds of protein ratio calculation
for a large number of permuted decoy datasets in which
the peptide-protein assignment has been scrambled.
Calculated p-values were adjusted for multiple testing
using a FDR-controlling procedure, yielding protein ratio
q-values reported in Table 2.
Quantitative analysis of selected proteins using multiple
reaction monitoring
We have selected a subset of proteins from the Differ-
ential Protein List shown in Table 2 for further analysis
of non-pooled, individual samples using the multiple
reaction monitoring (MRM) technique, used in con-
junction with stable-isotope-labeled peptide standards
(SIS). The presence of natural MRM transitions for
peptides from 17 proteins was first checked in samples
of urine collected separately from healthy volunteers.
Only for nine proteins the natural transitions corre-
sponding to selected peptides yielded satisfactory results
and SIS peptides were generated for these. The transi-
tions for peptides corresponding to the remaining eight
Bakun et al. Clinical Proteomics 2012, 9:13 Page 12 of 13
http://www.clinicalproteomicsjournal.com/content/9/1/13proteins could not be detected with a sufficient signal to
noise ratio.
Finally a set of peptides, corresponding to nine pro-
teins, used for further MRM analysis of individual
ADPKD and control samples, consisted of 14 peptides:
1. Antithrombin-III – peptide: TSDQIHFFFAK, peptide:
FATTFYQHLADSK
2. Cystatin-M - peptide: DLSPDDPQVQK, peptide:
AQSQLVAGIK
3. Transthyretin – peptide: AADDTWEPFASGK
4. Retinol-binding protein 4 – peptide: YWGVASFLQK,
peptide: DPNGLPPEAQK
5. Proactivator polypeptide – peptide:
EIVDSYLPVILDIIK, peptide: LVGYLDR
6. Apolipoprotein A-IV – peptide:
SELTQQLNALFQDK, peptide: LLPHANEVSQK
7. Complement C3 – peptide:TIYTPGSTVLYR
8. Histidine-rich glycoprotein – peptide: DGYLFQLLR
9. Myocilin – peptide: YELNTETVK
Specific tryptic peptide sequences, to be used for SIS
peptide synthesis, were selected for the nine proteins
based on the number of observations in the PeptideAtlas
MS/MS database (http://www.peptideatlas.org/, Institute
for Systems Biology, Seattle, WA), and on specific cri-
teria required in SIS peptides such as length and lack of
amino acid modifications [21,22]. SIS peptides were
synthesized by JPT Peptide Technologies GmbH using
the SpikeTides_L option (JPT Peptide Technologies
GmbH, Berlin, Germany) using isotopically labeled
C-terminal amino acids, [13C6,
15 N2]-Lys (98% isotopic en-
richment) or [13C6,
15 N4]-Arg (98% isotopic enrichment).
MRM analysis was performed using a Waters Xevo TQ
mass spectrometer (Waters, MA, USA) coupled to a
Waters nanoAcquity UPLC via a Zspray Nanoflow
source with a 10 μm SilicaTip PicoTip emitter (New
Objective, MA, USA). Mobile phase A was 0.1% formic
acid (Sigma-Aldrich) in LC-MS grade water (J.T.Baker,
Netherlands), and mobile phase B was LC-MS grade
acetonitrile (J.T.Baker) with 0.1% formic acid. Peptides
were loaded onto a Waters Symmetry C18 pre-column
(180 μm x 20 mm, 5 μm particle size) and separated using
a 40 min LC run, with a 27 min gradient of mobile
phase B changing from 1 to 45% on a Waters nanoAcquity
UPLC BEH130 C18 Column (100 μm x 100 mm, 1.7 μm
particle size). Other MS instrument parameters included
a capillary voltage of 3.1 kV, a purge gas flow of 100 L/h,
cone gas flow of 5 L/h, NanoFlow gas set at 1.0 Bar, and
a source temperature of 150°C. MRM parameters were
empirically optimized using pure SIS peptides to generate
the highest possible signal for each individual peptide
and resulting ion fragments. The optimal charge state
and optimal cone voltage were determined for each SISpeptide by injecting 1 pmol (in 0.1% formic acid) on-
column and ramping the cone voltage from 20 to 70 V in
5 V steps while gating all the possible parent ion charge
states (2+, 3+, 4+) using the selected ion recording (SIR)
function controlled by the Waters MassLynx V4.1 soft-
ware. The daughter ions generating the highest possible
signal and their individual, optimal collision energy (CE)
voltages were determined empirically by injecting 1 pmol
(in 0.1% formic acid) of SIS peptide on-column and
ramping the CE voltage up and down five 2 V steps from
that suggested by the Skyline Ver. 1.3 software (University
of Washington, MacCoss Lab, Department of Genome
Sciences, UW) for the Waters Xevo instrument. All
possible b- and y-series fragment ions for both 2+ and 3+
precursor ion charge states spanning a m/z range from
300 to 1500 were tested. MRM scans for optimization of
MRM Q1/Q3 ion pairs were conducted with the opti-
mized cone voltages with the Span setting set to 0 and
with dwell times of 10 milliseconds for each transition.
From this data, using the Skyline Ver. 1.3 software, the
5 transitions that produced the strongest signals were
selected on a per-peptide basis, with a preference toward
higher-mass y series ions if the abundances were similar.
These top 5 transitions were then checked for signal
interferences when present in a sample-digest back-
ground. The SIS peptide mix was analyzed by LC-MRM/
MS using transitions for heavy (SIS) and natural
(endogenous) peptides, both in buffer and in a sample
digest. Identical MRM acquisition parameters were used
for the heavy and natural forms of each peptide, while
taking into account the Q1/Q3 mass differences due to
the stable-isotope label. The transitions that maintained
the same relative intensities in both the buffer and sam-
ple were considered as interference free. This analysis
is also used to determine the retention time as well as
confirm the identity of the ion signals observed for
natural and heavy peptides, thus verifying the identity
of the natural peptides which co-elute with the corre-
sponding SIS peptides.
MRM analysis was performed on a new set of 52
samples (27 ADPKD vs. 25 healthy controls), with an in-
jection volume of 4 μl resulting in 2 μg of protein digest
on-column. Samples were prepared basically as for
iTRAQ pooling analysis, see Sample filtration section.
First, from each sample, an aliquot of protein fraction
containing 10 μg of total protein was transferred to sila-
nized vials. Then the volume of each sample was brought
to 30 μl using 100 mM solution of NH4HCO3. 100 mM
DTT (Sigma Cat no D8161-5 G) was added to the
samples to the final concentration of 10 mM and incu-
bated at 56°C for 40 min. To block reduced cysteines
0.5 M iodoacetamide (Sigma Cat no I1149-5 G) to the
final concentration of 50 mM was used and the sample
was incubated at room temperature for 30 minutes in
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samples in 1:20 vol./vol. ratio and incubated at 37°C over-
night. Finally, trifluoroacetic acid was added to digested
protein samples to reduce pH to 2 and inactivate trypsin.
Peptide standards were added to the samples post di-
gestion as a SIS mixture in which individual SIS pep-
tides were balanced to obtain at least a ratio of 1:10
between the endogenous natural peptide and the corre-
sponding SIS peptide in a positive sample. All MRM
data was processed using the Skyline Ver. 1.3 software
with default values for peak integration and Savitzky-
Golay peak smoothing. All integrated peaks were
manually inspected to ensure correct peak detection
and accurate integration. All peptides were targeted
using 5 MRM ion pairs per peptide unless an interfer-
ence was found in a transition then reducing that num-
ber to four transitions per peptide. The integrated peak
areas for the individual transitions detecting the 4–5
ion fragments per peptide were summed. The relative
protein amounts in the samples are reported as Peak
Area Ratios To Heavy, which refers to the ratio of the
integrated area of the endogenous (natural) peak to the
integrated area of the corresponding standard (SIS)
peptide.
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